

ASX Announcement

26 June 2026

## BlinkLab Provides Update on European ADHD Study

### Highlights

- European ADHD study recruitment and BlinkLab neurometric data collection completed, with approximately 375 children enrolled and tested.
- Final study analysis expected in the coming weeks, early in Q3 CY 2026, following completion of the comprehensive clinical diagnostic review process required to establish the study's diagnostic reference standard.
- Quality-control review confirms the BlinkLab dataset is highly consistent, complete and suitable for all planned analyses, with no issues identified in data collection or study execution.

**BlinkLab Limited (ASX: BB1)** ("BlinkLab" or the "Company") provides an update on its European ADHD study being conducted in collaboration with Mental Care Group ("MCG"). The study has completed participant recruitment and BlinkLab's neurometric data collection, with approximately 375 children enrolled.

All BlinkLab dataset has undergone quality review and the Company is pleased with the quality and completeness of the data collected.

The current study follows BlinkLab's previously announced pilot ADHD study with Mental Care Group<sup>1</sup>, which identified objective neurometric response patterns in children with ADHD that were distinct from those previously observed in autism studies. These encouraging findings provided the basis for expanding the research into the current larger clinical study, which is designed to evaluate BlinkLab's objective measures against comprehensive clinical ADHD diagnoses.

The final stage of the study requires completion of the clinical diagnostic reference dataset, which will be used to evaluate BlinkLab's objective neurometric measures against current clinical diagnostic standards for ADHD. Establishing a comprehensive and accurate diagnostic reference standard is an important component of the study and is necessary to support robust evaluation of BlinkLab's technology<sup>2,3</sup>.

BlinkLab will provide a further update once the final diagnostic dataset has been received and the study analyses have been completed.

<sup>1</sup> ASX Announcement (30 July 2024) – "BlinkLab Partners with Mental Care Group in Europe to Improve and Accelerate the Diagnostic Evaluation of ADHD"

<sup>2</sup> Merten EC, Cwik JC, Margraf J, Schneider S. Overdiagnosis of mental disorders in children and adolescents (in developed countries). *Child Adolesc Psychiatry Ment Health*. 2017 Jan 17;11:5. doi: 10.1186/s13034-016-0140-5. PMID: 28105068; PMCID: PMC5240230.

<sup>3</sup> Kazda L, Bell K, Thomas R, McGeechan K, Sims R, Barratt A. Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review. *JAMA Netw Open*. 2021 Apr 1;4(4):e215335. doi: 10.1001/jamanetworkopen.2021.5335. PMID: 33843998; PMCID: PMC8042533.

**BlinkLab Chairman, Brian Leedman, commented:**

*“We’re pleased to have completed recruitment and data collection for this important study. BlinkLab collects objective neurometric data in just minutes, but today’s clinical ADHD assessment process for children and adolescents takes much longer because it relies on comprehensive specialist evaluations and clinical judgment. Study analysis cannot be completed until all clinical diagnoses have been finalized and documented. This is almost complete and highlights the problem BlinkLab is committed to solve: bringing objective, fast measurements to a field that has long relied on subjective, time-consuming assessments. We look forward to reporting the study results in the coming weeks.”*

**This announcement has been authorised for release by the Board of BlinkLab Limited.**

For further information please contact:

**Dr Henk-Jan Boele**  
Managing Director & CEO  
henkjan@blinklab.org  
M: +31 (0) 611 132 247

**Brian Leedman**  
Non-Executive Chairman  
brian@blinklab.org  
M: +61 (0) 412 281 780

**About BlinkLab Limited**

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.